Literature DB >> 6099268

(+)- and (-)-3-PPP exhibit different intrinsic activity at striatal dopamine autoreceptors controlling dopamine synthesis.

D Clark, S Hjorth, A Carlsson.   

Abstract

Both enantiomers of the dopamine analogue 3-(3-hydroxyphenyl)-N-n-propylpiperidine (3-PPP; 0.5-32 mg/kg s.c.) dose dependently reduced the increase in striatal dopamine (DA) synthesis rate produced by gamma-butyrolactone (GBL). Whereas (+)-3-PPP completely prevented the action of GBL, (-)-3-PPP was only partially effective. In addition, (-)-3-PPP partially antagonised the inhibitory action of apomorphine on the GBL-induced increase in DA synthesis rate. These findings suggest that (+)- and (-)-3-PPP act as full and partial agonists respectively, at striatal DA autoreceptors controlling DA synthesis.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6099268     DOI: 10.1016/0014-2999(84)90694-0

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  12 in total

1.  Dopamine D-2 receptor agonist-induced behavioural depression: critical dependence upon postsynaptic dopamine D-1 function. A behavioural and biochemical study.

Authors:  D M Jackson; S B Ross; L G Larsson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-10       Impact factor: 3.000

2.  Is inhibition of striatal synaptosomal tyrosine hydroxylation by dopamine agonists a measure of dopamine autoreceptor function?

Authors:  C J Fowler; G Thorell; M Andersson; O Magnusson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-10       Impact factor: 3.000

3.  Effects of the partial dopamine receptor agonists SDZ 208-911, SDZ 208-912 and terguride on central monoamine receptors. A behavioral, biochemical and electrophysiological study.

Authors:  K Svensson; A Ekman; M F Piercey; W E Hoffmann; J T Lum; A Carlsson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-09       Impact factor: 3.000

4.  Anxiolytic-like action of the 3-PPP enantiomers in the Vogel conflict paradigm.

Authors:  S Hjorth; A Carlsson; J A Engel
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

5.  Dopamine D-2 agonists with high and low efficacies: differentiation by behavioural techniques.

Authors:  J Arnt; J Hyttel
Journal:  J Neural Transm Gen Sect       Date:  1990

Review 6.  Dopamine-receptor agonists: mechanisms underlying autoreceptor selectivity. I. Review of the evidence.

Authors:  D Clark; S Hjorth; A Carlsson
Journal:  J Neural Transm       Date:  1985       Impact factor: 3.575

7.  Central dopaminergic properties of HW-165 and its enantiomers; trans-octahydrobenzo(f)quinoline congeners of 3-PPP.

Authors:  S Hjorth; K Svensson; A Carlsson; H Wikström; B Andersson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1986-07       Impact factor: 3.000

8.  An electrophysiological analysis of the actions of the 3-PPP enantiomers on the nigrostriatal dopamine system.

Authors:  D Clark; G Engberg; E Pileblad; T H Svensson; A Carlsson; A S Freeman; B S Bunney
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-06       Impact factor: 3.000

9.  Modifications of sleep parameters in the rat by (+)- and (-)-3-PPP.

Authors:  S Kafi-de St Hilaire; J Y Sovilla; S Hjorth; J M Gaillard
Journal:  J Neural Transm       Date:  1985       Impact factor: 3.575

10.  Sub-chronic administration of (-)-3-PPP and central dopamine receptor sensitivity changes.

Authors:  S Hjorth; D Clark; K Svensson; A Carlsson; O Thorberg
Journal:  J Neural Transm       Date:  1985       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.